abstract |
The present invention provides a heterocyclic substituted tetracyclic compound that inhibits HCV viral replication or replicon activity and is useful for treating or preventing HCV infection in patients. A compound represented by the following formula: Wherein R 1 and each R 1A are H, R 3 is an optionally substituted 5-thiazolyl group, R 5 is H and an alkyl group, and R 7 is a specific substituent such as a heterocyclic group. And R8 is an alkyl group). [Selection figure] None |